甲基化氨酸代谢物作为临床状态的生物标志物和对5型固酶抑制的反应,在患有丰循环的患者中
Ari Cedars1, Cedric Manlhiot1, Bhargava Kumar Chinni1
1Johns Hopkins University Baltimore MD USA.
Journal of the American Heart Association
|March 26, 2025
概括
抑制氧化 (NO) 生产的代谢物,如不对称的二甲基氨酸 (ADMA),与Fontan循环患者的不良结果有关. 这些NO路径调节器可以预测运动能力和对5型固酶抑制剂 (PDE5is) 的反应.
科学领域:
- 心血管研究研究心血管研究
- 代谢学 代谢学 代谢学
- 生理学 生理学 生理学
背景情况:
- 患有Fontan循环的患者的治疗选择有限,他们对氧化物 (NO) 途径调节剂 (如5型固酶抑制剂 (PDE5is) 感兴趣.
- 此前在该人群中使用PDE5is的临床试验已经产生了不一致的结果.
- 关于NO通路与Fontan循环患者的临床状况之间的相互作用,存在重大知识差距.
研究的目的:
- 为了研究NO途径代谢物度与Fontan循环患者的临床结果之间的关联.
- 为了确定这些代谢物和运动能力之间的关系.
- 评估NO途径代谢物对PDE5抑制剂反应的预测值.
主要方法:
- 使用液态染色体-质谱学的有针对性的代谢分析.
- 量化血NO途径代谢物度在两个特征良好的患者队列中.
- 调查代谢物水平,临床结果,运动能力和PDE5i反应之间的关联.
主要成果:
- 不对称二甲基氨酸 (ADMA) 的血度升高,这是一种NO生产抑制剂,与住院或死亡风险增加相关.
- 较高的ADMA和对称二甲基氨酸 (SDMA) 水平与低于平均水平的峰值氧气吸收患者的基线运动能力降低有关.
- 随着时间的推移,ADMA和SDMA度的变化预测了运动能力的变化,PDE5i (乌迪纳菲尔) 治疗改变了这种关联.
- 基线ADMA和SDMA水平预测PDE5的响应是在低于正常的氧气吸收峰值的患者中.
结论:
- 血中NO流量抑制剂 (ADMA,SDMA) 度与不良临床结果和在Fontan循环中减弱的运动能力有关.
- 这些代谢物的变化表明NO流量增加与提高的运动能力相关.
- 在Fontan患者中,ADMA和SDMA显示出作为临床状态的生物标志物和PDE5i反应的预测因素的潜力.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K